A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma, Bladder Cancer, Nsclc, Urothelial Carcinoma
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologically confirmed locally advanced or metastatic melanoma, locally advanced or metastatic urothelial carcinoma, or metastatic non-small cell lung cancer (NSCLC) 2. Patients must not have received prior interleukin-2 (IL-2) therapy 3. Significant toxic effect(s) of the most recent prior chemotherapy must be resolved (except alopecia and sensory neuropathy).

You may not be eligible for this study if the following are true:

  • 1. Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s) 2. Patients who have an active, known or suspected autoimmune disease 3. History of allergy or hypersensitivity to study drug components.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.